Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
CONTEXT: 5α-Reductase 1 and 2 (SRD5A1, SRD5A2) inactivate cortisol to 5α-dihydrocortisol in addition to their role in the generation of DHT. Dutasteride (dual SRD5A1 and SRD5A2 inhibitor) and finasteride (selective SRD5A2 inhibitor) are commonly prescribed, but their potential metabolic effects have only recently been identified. OBJECTIVE: Our objective was to provide a detailed assessment of the metabolic effects of SRD5A inhibition and in particular the impact on hepatic lipid metabolism. DESIGN: We conducted a randomized study in 12 healthy male volunteers with detailed metabolic phenotyping performed before and after a 3-week treatment with finasteride (5 mg od) or dutasteride (0.5 mg od). Hepatic magnetic resonance spectroscopy (MRS) and two-step hyperinsulinemic euglycemic clamps incorporating stable isotopes with concomitant adipose tissue microdialysis were used to evaluate carbohydrate and lipid flux. Analysis of the serum metabolome was performed using ultra-HPLC-mass spectrometry. SETTING: The study was performed in the Wellcome Trust Clinical Research Facility, Queen Elizabeth Hospital, Birmingham, United Kingdom. MAIN OUTCOME MEASURE: Incorporation of hepatic lipid was measured with MRS. RESULTS: Dutasteride, not finasteride, increased hepatic insulin resistance. Intrahepatic lipid increased on MRS after dutasteride treatment and was associated with increased rates of de novo lipogenesis. Adipose tissue lipid mobilization was decreased by dutasteride. Analysis of the serum metabolome demonstrated that in the fasted state, dutasteride had a significant effect on lipid metabolism. CONCLUSIONS: Dual-SRD5A inhibition with dutasteride is associated with increased intrahepatic lipid accumulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Steroid 5α-reductase: two genes/two enzymes
Russell, D. W., & Wilson, J. D. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.000325 · Cited by 1,105
Lambert, J. E., Ramos–Roman, M. A., Browning, J. D., & Parks, E. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.049 · Cited by 1,069
Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.
Thigpen, A. E., Silver, R. I., Guileyardo, J. M., Casey, M. L., McConnell, J. D., & Russell, D. W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116665 · Cited by 727
Biomarkers of NAFLD progression: a lipidomics approach to an epidemic
Gorden, D. L., Myers, D. S., Ivanova, P. T., Fahy, E., Maurya, M. R., Gupta, S., Min, J., Spann, N. J., McDonald, J. G., Kelly, S. L., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p056002 · Cited by 372
Self-citation5 α-reductase activity in polycystic ovary syndrome
Stewart, P. M., Edwards, C. R. W., Shackleton, C. H. L., & Beastall, G. H. (1990) · The Lancet · doi:10.1016/0140-6736(90)90664-q · Cited by 189
Regulation of Lipogenesis by Glucocorticoids and Insulin in Human Adipose Tissue
Gathercole, L. L., Morgan, S. A., Bujalska, I. J., Hauton, D., Stewart, P. M., & Tomlinson, J. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026223 · Cited by 150
Self-citationA Switch in Hepatic Cortisol Metabolism across the Spectrum of Non Alcoholic Fatty Liver Disease
Ahmed, A., Rabbitt, E., Brady, T., Brown, C., Guest, P., Bujalska, I. J., Doig, C., Newsome, P. N., Hubscher, S., Elias, E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029531 · Cited by 115
Self-citationJuang, P. S., Peng, S., Allehmazedeh, K., Shah, A., Coviello, A. D., & Herbst, K. L. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12368 · Cited by 36
Cited by
Luukkonen, P. K., Sädevirta, S., Zhou, Y., Kayser, B., Ali, A., Ahonen, L., Lallukka, S., Pelloux, V., Gaggini, M., Jian, C., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0071 · Cited by 428
“which increase the risk of cardiovascular disease independent of LDL cholesterol (18).”
BackgroundSelf-citationNonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
O’Reilly, M. W., Kempegowda, P., Walsh, M., Taylor, A. E., Manolopoulos, K. N., Allwood, J. W., Semple, R. K., Hebenstreit, D., Dunn, W. B., Tomlinson, J. W., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00947 · Cited by 215
“The enzyme 5a-reductase type 1 (SRD5A1) activates T in peripheral target tissues to the most potent androgen, DHT, and is highly expressed in adipose tissue (24).”
Self-citationPrete, A., Taylor, A. E., Bancos, I., Smith, D. J., Foster, M. A., Kohler, S., Fazal-Sanderson, V., Komninos, J., O’Neil, D. M., Vassiliadi, D. A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa133 · Cited by 96
Self-citationHaider, K. S., Haider, A., Saad, F., Doros, G., Hanefeld, M., Dhindsa, S., Dandona, P., & Traish, A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14122 · Cited by 82
Metadata
- Authors
- Hazlehurst, J. M., Oprescu, A. I., Nikolaou, N., Di Guida, R., Grinbergs, A. E. K., Davies, N. P., Flintham, R. B., Armstrong, M. J., Taylor, A. E., Hughes, B. A., Yu, J., Hodson, L., Dunn, W. B., & Tomlinson, J. W.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-01
- Volume
- 101
- Issue
- 1
- Pages
- 103-113
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2232080468
- Cited by
- 71
- References
- 10
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man. https://app.cochat.ai/papers/10.1210/jc.2015-2928
- The paper
- Hazlehurst, J. M., Oprescu, A. I., Nikolaou, N., Di Guida, R., Grinbergs, A. E. K., Davies, N. P., Flintham, R. B., Armstrong, M. J., Taylor, A. E., Hughes, B. A., Yu, J., Hodson, L., Dunn, W. B., & Tomlinson, J. W. (2016). Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2015-2928
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.